Featured Publications
Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies
De Aquino JP, Parida S, Avila-Quintero VJ, Flores J, Compton P, Hickey T, Gómez O, Sofuoglu M. Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies. Drug And Alcohol Dependence 2021, 228: 109097. PMID: 34601272, PMCID: PMC8595687, DOI: 10.1016/j.drugalcdep.2021.109097.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderExperimental pain studiesAbuse potentialRespiratory depressionAcute painPain studiesUse disordersSystematic reviewGreater abuse potentialHigh-potency opioidsMethadone-maintained personsSignificant pain reliefRespiratory depressant effectsHigh-potency compoundsOpioid naïveAgonist therapyOpioid dosesPain reliefAnalgesic effectSevere painDepressant effectAdditional dosesStudy qualityHealthy persons
2023
Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study
De Aquino J, Meyerovich J, Xie C, Ranganathan M, Compton P, Pittman B, Rogan M, Sofuoglu M. Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study. Addiction Biology 2023, 28: e13317. PMID: 37644897, PMCID: PMC10468603, DOI: 10.1111/adb.13317.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist therapyAgonist therapyMethadone dosesMethadone therapyPain sensitivityUse disordersPlacebo-controlled laboratory studySynergistic antinociceptive effectCognitive adverse effectsSingle oral dosesRisk-benefit profilePain sensitivity measuresCannabinoid receptor systemAntinociceptive effectTHC doseOral dosesOpioid agonistsAcute effectsCannabinoid agonistsPreclinical studiesAbuse potentialOpioid crisisTherapyReceptor systemDeveloping non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence
Oliveira D, Fontenele R, Weleff J, Sofuoglu M, De Aquino J. Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence. International Review Of Psychiatry 2023, 35: 377-396. PMID: 38299655, PMCID: PMC10835074, DOI: 10.1080/09540261.2023.2229430.Peer-Reviewed Original ResearchOpioid agonist therapyOpioid use disorderNon-opioid analgesicsUse disordersNon-opioid analgesic therapyAlpha-2 adrenergic agonistsMajor public health concernGlial activation inhibitorNon-opioid therapeuticsNovel analgesic strategiesPotential of cannabinoidsPrior opioid exposureOpioid-dependent individualsOpioid-dependent populationsAbuse liability assessmentPublic health concernAnalgesic strategiesAgonist therapyAnalgesic therapyOpioid exposureOUD treatmentPharmacokinetic interactionsGABAergic drugsSignificant morbidityPain types
2020
Rapid Transition From Methadone to Buprenorphine Utilizing a Micro-dosing Protocol in the Outpatient Veteran Affairs Setting.
De Aquino J, Fairgrieve C, Klaire S, Garcia-Vassallo G. Rapid Transition From Methadone to Buprenorphine Utilizing a Micro-dosing Protocol in the Outpatient Veteran Affairs Setting. Journal Of Addiction Medicine 2020, 14: e271-e273. PMID: 32011408, PMCID: PMC7392785, DOI: 10.1097/adm.0000000000000618.Peer-Reviewed Original ResearchConceptsOpioid use disorderPrecipitated withdrawalTreatment of opioid use disorderCessation of methadoneMicro-dose protocolRisk of precipitated withdrawalMethadone to buprenorphineOpioid agonist therapyTransition to buprenorphineAgonist therapyOpioid useOutpatient protocolUse disorderOutpatient settingVeterans Affairs settingsBuprenorphineMethadonePsychiatry settingWithdrawalTransition protocolDemonstrating feasibilityInductionOpioidTherapyPatients